Tango Therapeutics, Inc. Other Noncash Income (Expense)
Tango Therapeutics, Inc. (TNGX) reported Other Noncash Income (Expense) of -$3.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Operating Activities
us-gaap:OtherNoncashIncomeExpense · last filed 2026-08-11
- Tango Therapeutics, Inc. other noncash income (expense) for the quarter ending 2026-06-30 was $18.00K, a 1700.00% increase year-over-year.
- Tango Therapeutics, Inc. other noncash income (expense) for the quarter ending 2026-03-31 was -$21.00K, a 137.50% decline year-over-year.
- Tango Therapeutics, Inc. other noncash income (expense) for the quarter ending 2025-12-31 was $19.00K, a 90.00% increase year-over-year.
- Tango Therapeutics, Inc. other noncash income (expense) for the quarter ending 2025-09-30 was $1.00K.
- Tango Therapeutics, Inc. other noncash income (expense) for fiscal 2025 was $77.00K.
- Tango Therapeutics, Inc. other noncash income (expense) for fiscal 2024 was -$23.00K.
- Tango Therapeutics, Inc. other noncash income (expense) for fiscal 2023 was -$22.00K, a 103.29% decline from fiscal 2022.
- Tango Therapeutics, Inc. other noncash income (expense) for fiscal 2022 was $669.00K.
| Period end | Other Noncash Income (Expense) 3 month | Other Noncash Income (Expense) 3 month as first filed | Other Noncash Income (Expense) 6 month | Other Noncash Income (Expense) 6 month as first filed | Other Noncash Income (Expense) 9 month | Other Noncash Income (Expense) 9 month as first filed | Other Noncash Income (Expense) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $18.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$3.00K 10-Q · filed 2026-08-11 | $16.00K derived: sum of 3 quarters · filed 2026-08-11 | $17.00K derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2026-03-31 | -$21.00K 10-Q · filed 2026-05-13 | -$2.00K derived: sum of 2 quarters · filed 2026-05-13 | -$1.00K derived: sum of 3 quarters · filed 2026-05-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-12-31 | $19.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $20.00K derived: sum of 2 quarters · filed 2026-03-05 | $21.00K derived: sum of 3 quarters · filed 2026-08-11 | $77.00K 10-K · filed 2026-03-05 | |||
| 2025-09-30 | $1.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.00K derived: sum of 2 quarters · filed 2026-08-11 | $58.00K 10-Q · filed 2025-11-04 | $68.00K derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-06-30 | $1.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | $57.00K 10-Q · filed 2026-08-11 | $67.00K derived: sum of 3 quarters · filed 2026-08-11 | $67.00K derived: sum of 4 quarters · filed 2026-08-11 | |||
| 2025-03-31 | $56.00K 10-Q · filed 2026-05-13 | $66.00K derived: sum of 2 quarters · filed 2026-05-13 | $66.00K derived: sum of 3 quarters · filed 2026-05-13 | $23.00K derived: sum of 4 quarters · filed 2026-05-13 | |||
| 2024-12-31 | $10.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $10.00K derived: sum of 2 quarters · filed 2026-03-05 | -$33.00K derived: sum of 3 quarters · filed 2026-03-05 | -$23.00K 10-K · filed 2026-03-05 | |||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$43.00K derived: sum of 2 quarters · filed 2025-11-04 | -$33.00K 10-Q · filed 2025-11-04 | -$33.00K derived: sum of 4 quarters · filed 2026-03-05 | |||
| 2024-06-30 | -$43.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | -$33.00K 10-Q · filed 2025-08-05 | -$33.00K derived: sum of 3 quarters · filed 2026-03-05 | ||||
| 2024-03-31 | $10.00K 10-Q · filed 2025-05-12 | $10.00K derived: sum of 2 quarters · filed 2026-03-05 | |||||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | -$22.00K 10-K · filed 2026-03-05 | |||||
| 2023-09-30 | -$22.00K 10-Q · filed 2024-11-06 | ||||||
| 2023-03-31 | -$4.00K 10-Q · filed 2024-05-08 | $889.00K 10-Q · filed 2023-05-09 | $680.00K derived: sum of 2 quarters · filed 2025-02-27 | $671.00K derived: sum of 3 quarters · filed 2025-02-27 | $719.00K derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $684.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $675.00K derived: sum of 2 quarters · filed 2025-02-27 | $723.00K derived: sum of 3 quarters · filed 2025-02-27 | $669.00K 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$9.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $39.00K derived: sum of 2 quarters · filed 2023-11-08 | -$15.00K 10-Q · filed 2023-11-08 | $204.00K 10-Q · filed 2022-11-10 | -$98.00K derived: sum of 4 quarters · filed 2023-11-08 | ||
| 2022-06-30 | $48.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$6.00K 10-Q · filed 2023-08-07 | -$15.00K 10-Q · filed 2022-08-10 | -$89.00K derived: sum of 3 quarters · filed 2023-08-07 | -$142.00K derived: sum of 4 quarters · filed 2023-08-07 | ||
| 2022-03-31 | -$54.00K 10-Q · filed 2023-05-09 | -$137.00K derived: sum of 2 quarters · filed 2023-05-09 | -$190.00K derived: sum of 3 quarters · filed 2023-05-09 | -$250.00K derived: sum of 4 quarters · filed 2023-05-09 | |||
| 2021-12-31 | -$83.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-27 | -$136.00K derived: sum of 2 quarters · filed 2023-03-27 | -$196.00K derived: sum of 3 quarters · filed 2023-03-27 | -$254.00K 10-K · filed 2023-03-27 | |||
| 2021-09-30 | -$53.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | -$113.00K derived: sum of 2 quarters · filed 2022-11-10 | -$171.00K 10-Q · filed 2022-11-10 | -$261.00K derived: sum of 4 quarters · filed 2022-11-10 | |||
| 2021-06-30 | -$60.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | -$118.00K 10-Q · filed 2022-08-10 | -$208.00K derived: sum of 3 quarters · filed 2022-08-10 | ||||
| 2021-03-31 | -$58.00K 10-Q · filed 2022-05-11 | -$148.00K derived: sum of 2 quarters · filed 2022-05-11 | |||||
| 2020-12-31 | -$90.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-28 | $17.00K 10-K · filed 2022-03-28 | |||||
| 2020-09-30 | $107.00K 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Edgewise Therapeutics, Inc. (EWTX) | United States | $4.470B | -22.23 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Veradermics, Inc (MANE) | United States | $4.839B | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |